# Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

> **NCT03295786** · PHASE1,PHASE2 · COMPLETED · sponsor: **Herantis Pharma Plc.** · enrollment: 17 (actual)

## Conditions studied

- Parkinson Disease
- Movement Disorders
- Neurodegenerative Diseases
- Nervous System Diseases
- Brain Diseases

## Interventions

- **DRUG:** Cerebral Dopamine Neurotrophic Factor
- **DEVICE:** Renishaw Drug Delivery System

## Key facts

- **NCT ID:** NCT03295786
- **Lead sponsor:** Herantis Pharma Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2019-12-19
- **Final completion:** 2019-12-19
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295786, "Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03295786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*